TMCnet News

Research and Markets: Global miRNA Research and Diagnostics Markets Report 2014
[November 18, 2014]

Research and Markets: Global miRNA Research and Diagnostics Markets Report 2014


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/f6kwgn/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering.

This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that do not produce protein, shut off gene transcription by base pairing with the target molecules.

They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, a large number of companies, both small biotechs and big pharmaceutical companies are committed to miRNA diagnostics.

As part of its coverage of ths topic, this report includes the following:



  • Overview of miRNAs
  • Positive Factors for miRNA Diagnostic Technologies
  • Negative Factors
  • miRNAs and Neurological Disorders
  • miRNA and Metastatic Brain Lesions
  • Prostate Cancer Screening and miRNAs
  • miRNAs and Resistance to Anti-Cancer Drugs
  • Theoretical Limitations
  • Discussion of Patent Issues
  • Interviews with Industry Experts
  • Market Estimate

As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail:

  • Agilent (News - Alert) Technologies
  • AMSBIO
  • Applied Biosystems
  • DiamiR, LLC
  • Dicerna
  • Eisai Biomarkers and Personalized Medicine
  • Diagnostics
  • Genomic Health Inc.
  • Gensignia
  • GlaxoSmithKline Discovery and Molecular Toxicology
  • Groove Biopharma (formerly Mirina)
  • Hologic-Gen Probe Inc.
  • Illumina, Inc.
  • Isis Pharmaceuticals
  • Mello Biotechnology Inc.
  • Microlin Bio
  • MiRagen Therapeutics
  • MiRNA Therapeutics
  • Novartis
  • Pacific Edge Biotechnology
  • Prolias Technologies
  • Regulus Therapeutics
  • Rosetta Genomics
  • Santaris Pharma A/S
  • Sirnaomics, Inc.
  • Somagenics
  • Diagnostics: Small RNA Assays and Biomarker Validation
  • Tekmira Pharmaceuticals Corporation
  • Thermadiag
  • Thermo Fisher Scientific, Inc.

Key Topics Covered:


1. Executive Summary

2. Introduction

3. Current State of the Art

4. Companies Developing microRNA Diagnostic Technologies

5. Market Estimates and Forecasts

6. Interviews with Industry Experts: Biomarkers

7. The Future of miRNA-Based Diagnostics

For more information visit http://www.researchandmarkets.com/research/f6kwgn/mirna_research


[ Back To TMCnet.com's Homepage ]